De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control " always " matter?

被引：0
|
作者：
Lorini, L. [1 ,8 ]
Gili, R. [2 ]
Salvestrini, V. [3 ]
Morelli, I. [4 ]
Smussi, D. [5 ]
Petrelli, F. [6 ]
Bonomo, P.
Bossi, P. [1 ,7 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Via Manzoni 56, I-20089 Milan, Italy
[2] IRCCS Osped Policlin San Martino, Med Oncol Unit, I-16132 Genoa, Italy
[3] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[4] Univ Florence, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[5] Univ Brescia, Dept Med & Surg Specialties, Med Oncol Unit, Radiol Sci & Publ Hlth,ASST Spedali Civil, I-25123 Brescia, Italy
[6] ASST Bergamo Ovest, Oncol Unit, Treviglio, Italy
[7] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy
[8] Via Manzoni 56,0282241, I-20089 Rozzano, Italy
来源：
ORAL ONCOLOGY | 2024年 / 152卷
关键词：
De novo metastatic head and neck squamous; cell carcinoma; Radiation; Immunotherapy; Quality of Life; CLINICAL-PRACTICE GUIDELINES; NASOPHARYNGEAL CARCINOMA; RADIATION-THERAPY; OPEN-LABEL; CHEMOTHERAPY; DIAGNOSIS; SURVIVAL; CARE;
D O I：
10.1016/j.oraloncology.2024.106768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
De novo metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) constitutes 10% of recurrent/metastatic (RM) cases. Radiotherapy (RT) has a crucial role in the treatment of locally advanced HNSCC, however its application on RM diseases is still limited. The advent of immune checkpoint inhibitors (ICIs) improves the survival of RM HNSCC, however median overall survival is still limited. Integration of locoregional RT with ICIs in de novo metastatic HNSCC represents a promising treatment option. This perspective aims to explore the role of the combination of locoregional and systemic treatment in improving outcomes for synchronous de novo metastatic HNSCC patients and highlights the principal crucial point in decision making.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma
    Dizdar, Yavuz
    Ozkaya Toraman, Kubra
    Altun, Musa
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (02): : 177 - 183
  • [2] Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas
    Tang, Eliane
    Schwartz, Boris
    Limkin, Elaine
    Even, Caroline
    Blanchard, Pierre
    Haddy, Nadia
    Gorphe, Philippe
    Ferrand, Francois-Regis
    Tao, Yungan
    Nguyen, Thanh-Van-France
    ACTA ONCOLOGICA, 2023, 62 (05) : 465 - 472
  • [3] Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma
    Rambeau, A.
    Bastit, V.
    Thureau, S.
    Thariat, J.
    Moldovan, C.
    Roge, M.
    Babin, E.
    Gery, B.
    Di Fiore, F.
    Florescu, C.
    Clatot, F.
    ORAL ONCOLOGY, 2019, 93 : 46 - 51
  • [4] Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Hsieh, Ronan W.
    Borson, Steven
    Tsagianni, Anastasia
    Zandberg, Dan P.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 146 - 151
  • [6] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [7] Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma
    Gauduchon, Thibault
    Neidhardt, Eve Marie
    Fayette, Jerome
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 175 - 183
  • [8] Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
    Specenier, Pol
    Vermorken, Jan B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (09) : 901 - 915
  • [9] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    ONCOLOGIST, 2018, 23 (02) : 225 - 233
  • [10] Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma
    Galot, Rachel
    van Marcke, Cedric
    Helaers, Raphael
    Mendola, Antonella
    Goebbels, Rose-Marie
    Caignet, Xavier
    Ambroise, Jerome
    Wittouck, Kyril
    Vikkula, Miikka
    Limaye, Nisha
    Machiels, Jean-Pascal H.
    ORAL ONCOLOGY, 2020, 104
12345